334
Views
2
CrossRef citations to date
0
Altmetric
CASE REPORT

Refractory Hypertension and Anemia in End-Stage Renal Disease: An Unusual Manifestation of Kimura's Disease

, , , M.D., , &
Pages 499-507 | Published online: 26 Aug 2009

Figures & data

Figure 1. Biopsy sample of inguinal mass showing intact follicular architecture with prominent infiltration by ecosinophils (hematoxylin and eosin, ×100).

Figure 1. Biopsy sample of inguinal mass showing intact follicular architecture with prominent infiltration by ecosinophils (hematoxylin and eosin, ×100).

Figure 2. Compare before and post treatment data: Panel A. After treatment, the patient's hemoglobin (from 7.7 to 9.2) and saturation of Fe/TIBC (from 36 to 49.7%) increased. The reduced ferritin levels (from 1361 to 543) indicate that result from increased iron utilization; Panel B. CRP level reduced (from 105 to 6) after treatment and the mean arterial blood pressure (from 118.66 ± 6.9 mmHg to 97.63 ± 5.2 mmHg) was easily controlled. No significant difference in serum renin and aldosterone level. Panel C. IgE (from 1350 to 1020) and eosinophil (from 19.5 to 0%) decreased after steroid treatment implicated the activity of Kimura's disease decreased.

Figure 2. Compare before and post treatment data: Panel A. After treatment, the patient's hemoglobin (from 7.7 to 9.2) and saturation of Fe/TIBC (from 36 to 49.7%) increased. The reduced ferritin levels (from 1361 to 543) indicate that result from increased iron utilization; Panel B. CRP level reduced (from 105 to 6) after treatment and the mean arterial blood pressure (from 118.66 ± 6.9 mmHg to 97.63 ± 5.2 mmHg) was easily controlled. No significant difference in serum renin and aldosterone level. Panel C. IgE (from 1350 to 1020) and eosinophil (from 19.5 to 0%) decreased after steroid treatment implicated the activity of Kimura's disease decreased.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.